ATE452188T1 - Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) - Google Patents
Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)Info
- Publication number
- ATE452188T1 ATE452188T1 AT05713300T AT05713300T ATE452188T1 AT E452188 T1 ATE452188 T1 AT E452188T1 AT 05713300 T AT05713300 T AT 05713300T AT 05713300 T AT05713300 T AT 05713300T AT E452188 T1 ATE452188 T1 AT E452188T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- multifunctional sina
- gene expression
- short interfering
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54348004P | 2004-02-10 | 2004-02-10 | |
| PCT/US2004/016390 WO2005019453A2 (en) | 2001-05-18 | 2004-05-24 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| PCT/US2005/004270 WO2005078097A2 (en) | 2004-02-10 | 2005-02-09 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE452188T1 true ATE452188T1 (de) | 2010-01-15 |
Family
ID=56290660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05713300T ATE452188T1 (de) | 2004-02-10 | 2005-02-09 | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7858769B2 (de) |
| EP (1) | EP1713915B1 (de) |
| JP (1) | JP2007523649A (de) |
| AT (1) | ATE452188T1 (de) |
| AU (1) | AU2005212433B2 (de) |
| CA (1) | CA2554212A1 (de) |
| WO (1) | WO2005078097A2 (de) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US20080207542A1 (en) * | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2005105995A2 (en) * | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| RU2008129711A (ru) * | 2005-12-19 | 2010-01-27 | Сирна Терапьютикс, Инк. (Us) | Опосредуемое интерференцией рнк ингибирование эксрессии гена вируса гепатита с (hcv) с использованием короткой интерферирующей нуклеиновой кислоты (кинк) |
| WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
| EP2121924A1 (de) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nukleinsäureverbindungen zur hemmung der vegf-familien-genexpression und anwendungen davon |
| CA2679757A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| JP2010525826A (ja) | 2007-05-03 | 2010-07-29 | ロゼッタ インファーマティックス エルエルシー | 癌を治療するためのｍｉｒ３４治療剤を含む組成物 |
| WO2009045457A2 (en) * | 2007-10-02 | 2009-04-09 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
| CN102711454B (zh) * | 2009-10-12 | 2015-05-20 | 杰西.L.S.奥 | 用于提高rna干扰剂的递送、表达或活性的方法和组合物 |
| US9243246B2 (en) | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
| KR101223484B1 (ko) * | 2010-10-05 | 2013-01-17 | 한국과학기술연구원 | 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| DE102011009470A1 (de) * | 2011-01-21 | 2012-08-09 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| EP3730618A1 (de) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai-mittel, zusammensetzungen daraus und verfahren zur verwendung davon zur behandlung von mit transthyretin (ttr) assoziierten krankheiten |
| AU2013296321B2 (en) | 2012-08-03 | 2019-05-16 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| IL292159B1 (en) | 2012-12-05 | 2026-04-01 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA compositions and methods of using them |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| KR102234623B1 (ko) | 2013-05-22 | 2021-04-02 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| EA038792B1 (ru) | 2013-05-22 | 2021-10-20 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| US10119136B2 (en) | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| CN113057959B (zh) | 2014-02-11 | 2024-07-16 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶（KHK）iRNA组合物及其使用方法 |
| TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物 |
| AU2015264038B2 (en) | 2014-05-22 | 2021-02-11 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (AGT) iRNA compositions and methods of use thereof |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TW202503057A (zh) | 2014-10-10 | 2025-01-16 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| KR102545316B1 (ko) | 2014-11-10 | 2023-06-22 | 알닐람 파마슈티칼스 인코포레이티드 | Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법 |
| JP2017535552A (ja) | 2014-11-17 | 2017-11-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法 |
| JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｒｅｖｅｒｓｉｒ（商標）化合物 |
| CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
| CA3205381A1 (en) * | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| CA2996873A1 (en) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof |
| KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| EP3469083A1 (de) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh) |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
| TW202434265A (zh) | 2017-07-10 | 2024-09-01 | 美商健贊公司 | 於患有血友病之個體中治療出血事件之方法及組成物 |
| EP3652317A1 (de) | 2017-07-13 | 2020-05-20 | Alnylam Pharmaceuticals, Inc. | Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung |
| US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| EP3728593A1 (de) | 2017-12-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen der high-mobility-group box-1 (hmgb1) und verfahren zur verwendung davon |
| MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| US20210332367A1 (en) | 2018-09-18 | 2021-10-28 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2020069055A1 (en) | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| AU2020279101B2 (en) | 2019-05-17 | 2025-07-24 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| EP4007812A1 (de) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung |
| EP4007811A2 (de) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4013870A1 (de) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung |
| US12503699B2 (en) | 2019-10-04 | 2025-12-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing UGT1a1 gene expression |
| EP4045652A1 (de) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür |
| WO2021081026A1 (en) | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| EP4051795A1 (de) | 2019-11-01 | 2022-09-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zu deren verwendung |
| WO2021092145A1 (en) | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| BR112022007795A2 (pt) | 2019-11-06 | 2022-07-05 | Alnylam Pharmaceuticals Inc | Administração extra-hepática |
| BR112022009216A2 (pt) | 2019-11-13 | 2022-08-02 | Alnylam Pharmaceuticals Inc | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) |
| US12565653B2 (en) | 2019-11-22 | 2026-03-03 | Alnylam Pharmaceuticals, Inc. | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof |
| KR20220115995A (ko) | 2019-12-13 | 2022-08-19 | 알닐람 파마슈티칼스 인코포레이티드 | 인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법 |
| WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| IL295445A (en) | 2020-02-10 | 2022-10-01 | Alnylam Pharmaceuticals Inc | Preparations and methods for silencing vegf-a expression |
| JP7735288B2 (ja) | 2020-02-18 | 2025-09-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法 |
| EP4114947A1 (de) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen |
| BR112022017822A2 (pt) | 2020-03-06 | 2022-11-08 | Alnylam Pharmaceuticals Inc | Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas |
| EP4121534A1 (de) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt) |
| TW202204615A (zh) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | 冠狀病毒ｉＲＮＡ組成物及其使用方法 |
| US20230190785A1 (en) | 2020-03-30 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| US12534731B2 (en) | 2020-04-01 | 2026-01-27 | Alnylam Pharmaceuticals, Inc. | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof |
| KR20230008729A (ko) | 2020-04-06 | 2023-01-16 | 알닐람 파마슈티칼스 인코포레이티드 | Myoc 발현을 사일런싱하기 위한 조성물 및 방법 |
| EP4133076A1 (de) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon |
| EP4133077A1 (de) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon |
| JP2023521094A (ja) | 2020-04-07 | 2023-05-23 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｓｃｎ９ａ発現をサイレンシングするための組成物および方法 |
| IL297702A (en) | 2020-04-27 | 2022-12-01 | Alnylam Pharmaceuticals Inc | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
| JP2023523790A (ja) | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法 |
| US20230183707A1 (en) | 2020-05-21 | 2023-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| EP4162050A1 (de) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation |
| WO2021252649A2 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression |
| WO2021257782A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
| WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| EP4225917A1 (de) | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon |
| CA3198823A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (de) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon |
| KR20230107625A (ko) | 2020-11-13 | 2023-07-17 | 알닐람 파마슈티칼스 인코포레이티드 | 응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법 |
| TW202237150A (zh) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物 |
| WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| EP4271696A2 (de) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat |
| EP4271695A2 (de) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs |
| EP4274896A1 (de) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4291654A2 (de) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen |
| EP4298220A1 (de) | 2021-02-25 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon |
| AU2022226098A1 (en) | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| JP2024508896A (ja) | 2021-03-04 | 2024-02-28 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法 |
| WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| EP4314296A2 (de) | 2021-03-29 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon |
| EP4314293A1 (de) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4330392A1 (de) | 2021-04-26 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transmembranprotease, serin 6 (tmprss6)-irna-zusammensetzungen und verfahren zur verwendung davon |
| WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| EP4341401A1 (de) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4347823A1 (de) | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4347822A2 (de) | 2021-06-04 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Irna-wirkstoffzusammensetzungen mit offenem leserahmen 72 (c9orf72) auf menschlichem chromosom 9 und verfahren zur verwendung davon |
| AR126070A1 (es) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4) |
| AU2022303164A1 (en) | 2021-06-30 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
| WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| MX2024000981A (es) | 2021-07-21 | 2024-02-12 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso. |
| AU2022316139A1 (en) | 2021-07-23 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
| WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
| CA3227852A1 (en) | 2021-08-03 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
| EP4381071A1 (de) | 2021-08-04 | 2024-06-12 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen und verfahren zur ausschaltung von angiotensinogen (att) |
| CN118076737A (zh) | 2021-08-13 | 2024-05-24 | 阿尔尼拉姆医药品有限公司 | 因子XII（F12）iRNA组合物及其使用方法 |
| JP2024538859A (ja) | 2021-08-31 | 2024-10-24 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法 |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| TW202328449A (zh) | 2021-09-24 | 2023-07-16 | 美商艾拉倫製藥公司 | 微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法 |
| CN118369427A (zh) | 2021-10-15 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | 肝外递送irna组合物及其使用方法 |
| EP4423272A2 (de) | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| JP2025522880A (ja) | 2022-06-30 | 2025-07-17 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ |
| EP4569113A1 (de) | 2022-09-15 | 2025-06-18 | Regeneron Pharmaceuticals, Inc. | 17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung |
| WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
| KR20260009305A (ko) | 2023-04-12 | 2026-01-19 | 알닐람 파마슈티칼스 인코포레이티드 | 이중 가닥 rna 제제의 간외 전달 |
| KR20260049597A (ko) | 2023-08-04 | 2026-04-14 | 알닐람 파마슈티칼스 인코포레이티드 | Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물 |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| WO2025076031A2 (en) | 2023-10-03 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0473576A4 (en) | 1989-05-19 | 1993-03-10 | Hem Research, Inc. | Short therapeutic dsrna of defined structure |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| PL172710B1 (pl) | 1992-07-02 | 1997-11-28 | Hybridon Inc | Samostabilizujacy sie oligonukleotyd PL PL |
| US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
| US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
| US6060456A (en) | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5587471A (en) | 1994-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Method of making oligonucleotide libraries |
| JPH08208687A (ja) | 1994-11-25 | 1996-08-13 | Sankyo Co Ltd | グリセリルオリゴヌクレオチド |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| WO2002096927A2 (en) | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20040161844A1 (en) | 1996-06-06 | 2004-08-19 | Baker Brenda F. | Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| CN1202246C (zh) | 1998-04-08 | 2005-05-18 | 联邦科学和工业研究组织 | 获得修饰表型的方法和措施 |
| CA2330574A1 (en) | 1998-04-29 | 1999-11-04 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| ATE489108T1 (de) | 1998-10-09 | 2010-12-15 | Vegenics Ltd | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| US5998206A (en) | 1999-02-23 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense inhibiton of human G-alpha-12 expression |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| KR20070118315A (ko) | 1999-04-21 | 2007-12-14 | 와이어쓰 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물 |
| BR0012325A (pt) | 1999-07-09 | 2002-05-21 | American Home Prod | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| WO2001038551A1 (en) | 1999-11-29 | 2001-05-31 | Cold Spring Harbor Laboratory | Regulation of polycomb group gene expression for increasing seed size in plants |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| AU2625501A (en) | 1999-12-30 | 2001-07-16 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| IT1316982B1 (it) | 2000-01-17 | 2003-05-26 | Univ Roma | Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi. |
| US6602857B1 (en) | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6831171B2 (en) | 2000-02-08 | 2004-12-14 | Yale University | Nucleic acid catalysts with endonuclease activity |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| EP1272630A2 (de) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methoden und zusammensetzungen zur interferenz durch rna |
| KR20020097198A (ko) | 2000-03-17 | 2002-12-31 | 베니텍 오스트레일리아 리미티드 | 유전자 사일런싱 |
| WO2001070944A2 (de) | 2000-03-22 | 2001-09-27 | Aventis Pharma Deutschland Gmbh | Nematoden als modellorganismen zur untersuchung neurodegenerativer erkrankungen und insbesonder der parkinsonschen erkrankung, verwendungen und verfahren zum auffinden von substanzen und genen, die bei der behandlung solcher erfrankungen eingesetz werden können, sowie identifizierung eines nematodengens. |
| GB0007268D0 (en) | 2000-03-24 | 2000-05-17 | Cyclacel Ltd | Cell cycle progression proteins |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| US6824972B2 (en) | 2000-05-22 | 2004-11-30 | Baylor College Of Medicine | Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-κB) activation |
| WO2001092513A1 (en) | 2000-05-30 | 2001-12-06 | Johnson & Johnson Research Pty Limited | METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU784231B2 (en) | 2000-06-23 | 2006-02-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II) |
| EP1311277A4 (de) | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | Methoden zur fibrose-modulation |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US6613567B1 (en) | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
| DE60135482D1 (de) | 2000-11-09 | 2008-10-02 | Cenix Bioscience Gmbh | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| EP1386004A4 (de) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| WO2003070887A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2004266311B2 (en) * | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003070896A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| DK2070939T3 (da) * | 2001-05-25 | 2014-06-23 | Univ Duke | Modulatorer af farmakologiske midler |
| JP4344858B2 (ja) | 2001-09-13 | 2009-10-14 | カリフォルニア インスティチュート オブ テクノロジー | 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法 |
| EP1445312B1 (de) | 2001-11-21 | 2012-12-26 | Astellas Pharma Inc. | Verfahren zur hemmung der genexpression |
| EP1325955A1 (de) | 2002-01-04 | 2003-07-09 | atugen AG | Verbindungen und Verfahren zur Identifizierung und/oder Validierung eines Targets |
| ATE556714T1 (de) | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| US7820632B2 (en) | 2002-02-14 | 2010-10-26 | City Of Hope | Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules |
| EP1432724A4 (de) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Durch rna-interferenz vermittelte inhibierung von map-kinase-genen |
| US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| AU2003219432B2 (en) | 2002-03-27 | 2010-04-01 | Pharmascience Inc. | Antisense IAP nucleobase oligomers and uses thereof |
| DK1389637T3 (da) | 2002-08-05 | 2012-09-03 | Silence Therapeutics Ag | Interfererende RNA-molekyler med stumpe ender |
| CA2881743A1 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| AU2003287464A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | 2'-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| JP3839453B2 (ja) | 2002-11-22 | 2006-11-01 | 株式会社バイオシンクタンク | Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム |
| JP2006519594A (ja) | 2003-02-11 | 2006-08-31 | イミューソル インコーポレイテッド | 所定のタンパク質ファミリー用に最適化したｓｉＲＮＡライブラリー |
| JP4605799B2 (ja) | 2003-04-02 | 2011-01-05 | ダーマコン， インコーポレイテッド | Ｒｎａ干渉において使用するための修飾ポリヌクレオチド |
| WO2005049821A1 (ja) | 2003-11-21 | 2005-06-02 | Bio-Think Tank Co., Ltd. | ＲＮＡｉ活性およびｍｉＲＮＡ活性の評価方法 |
| GB2424887B (en) | 2003-11-26 | 2008-05-21 | Univ Massachusetts | Sequence-specific inhibition of small RNA function |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
-
2005
- 2005-02-09 AT AT05713300T patent/ATE452188T1/de not_active IP Right Cessation
- 2005-02-09 CA CA002554212A patent/CA2554212A1/en not_active Abandoned
- 2005-02-09 US US10/597,755 patent/US7858769B2/en not_active Expired - Lifetime
- 2005-02-09 AU AU2005212433A patent/AU2005212433B2/en not_active Expired
- 2005-02-09 JP JP2006553239A patent/JP2007523649A/ja not_active Withdrawn
- 2005-02-09 EP EP05713300A patent/EP1713915B1/de not_active Expired - Lifetime
- 2005-02-09 WO PCT/US2005/004270 patent/WO2005078097A2/en not_active Ceased
-
2010
- 2010-11-16 US US12/947,609 patent/US20110118335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007523649A (ja) | 2007-08-23 |
| CA2554212A1 (en) | 2005-08-25 |
| US20110118335A1 (en) | 2011-05-19 |
| US7858769B2 (en) | 2010-12-28 |
| AU2005212433A1 (en) | 2005-08-25 |
| EP1713915A2 (de) | 2006-10-25 |
| US20080039412A1 (en) | 2008-02-14 |
| WO2005078097A3 (en) | 2005-10-27 |
| EP1713915B1 (de) | 2009-12-16 |
| WO2005078097A2 (en) | 2005-08-25 |
| AU2005212433B2 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE452188T1 (de) | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) | |
| DK2287306T3 (da) | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | |
| WO2003070918A3 (en) | Rna interference by modified short interfering nucleic acid | |
| WO2003070884A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2003070887A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2005084366A3 (en) | Transcription factor rna interference reagents and methods of use thereof | |
| EP1522583A3 (de) | Durch RNAi bewirkte Hemmung der Expression von dem Placental Growth Factor Gen mittels kleiner interfierender Nukleinsäuren (siNA) | |
| WO2003070197A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| EP1710307A3 (de) | Durch RNA-Interferenz vermittelte Hemmung der Genexpression unter Verwendung von siNA (short interfering nucleic acid) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |